NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sanegene Bio

Sanegene Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.sanegenebio.com/

Last Round

Series B

Dec 8, 2025

Total Funding Raised

$266.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sanegene Bio is a biotechnology company that develops RNA interference (RNAi) therapeutics for obesity, cardiometabolic, and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

LEAD platformRNAi therapeuticssiRNA therapeuticsgene silencingdrug delivery platformextra-hepatic deliveryobesity treatmentcardiometabolic diseaseautoimmune diseasehypertension treatmentnephropathy treatmentcomplement-mediated diseasessubcutaneous dosingbiotech licensingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sanegene Bio Comparables

Compare Sanegene Bio with similar companies based on industry and business-model similarity.

Sanegene Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Argo Biopharma
90%
Rona Therapeutics
85%
Vivatides Therapeutics
84%

Sanegene Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 8, 2025
StrategicNov 8, 2025
Series A ExtensionDec 1, 2023
Series AAug 31, 2021
Series AAug 1, 2021

Key People

Founding team and executive leadership

Marc Abrams

Chief Technology Officer Head, US Operations

Executive Team

Sanegene Bio Investors

Notable investors and investment history

Sanegene Bio investors
InvestorRounds
Alwin CapitalSeries A, Series A Extension
SymBiosis Capital ManagementSeries B
Lake Bleu CapitalSeries B
Shanghai Healthcare CapitalSeries A Extension
Oriza HoldingsSeries A, Series B, Series A Extension
Hillhouse InvestmentSeries B, Series A
Tianjin TEDA Science and Technology Investment Co., Ltd.Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2026

    Partnered with Genentech to advance RNAi programs.

  • Dec 8, 2025

    $110M round raised

Sanegene Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sanegene Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sanegene Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range32
Year Founded2021
Last FundingDec 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.